Michael J Dooley

Melbourne Health, Melbourne, Victoria, Australia

Are you Michael J Dooley?

Claim your profile

Publications (58)197.07 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Prospective surveillance of invasive mold diseases (IMDs) in haematology patients should be standard of care but is hampered by the absence of a reliable laboratory prompt and the difficulty of manual surveillance. We used a high throughput technology, natural language processing (NLP), to develop a classifier based on machine learning techniques to screen computed tomography (CT) reports supportive for IMDs. Patients and Methods: We conducted a retrospective case-control study of CT reports from the clinical encounter and up to 12-weeks after, from a random subset of 79 of 270 case patients with 33 probable/proven IMDs by international definitions, and 68 of 257 uninfected-control patients identified from 3 tertiary haematology centres. The classifier was trained and tested on a reference standard of 449 physician annotated reports including a development subset (n = 366), from a total of 1880 reports, using 10-fold cross validation, comparing binary and probabilistic predictions to the reference standard to generate sensitivity, specificity and area under the receiver-operating-curve (ROC). Results: For the development subset, sensitivity/specificity was 91% (95% CI 86% to 94%)/79% (95% CI 71% to 84%) and ROC area was 0.92 (95% CI 89% to 94%). Of 25 (5.6%) missed notifications, only 4 (0.9%) reports were regarded as clinically significant. Conclusion: CT reports are a readily available and timely resource that may be exploited by NLP to facilitate continuous prospective IMD surveillance with translational benefits beyond surveillance alone.
    PLoS ONE 09/2014; 9(9):e107797. DOI:10.1371/journal.pone.0107797 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic stem cell transplantation (SCT) is a complex procedure that requires specialized medication management. Providing clinical pharmacy services in the ambulatory setting is warranted, as medications are a common source of confusion for SCT patients and their carers. These patients were routinely managed via traditional ambulatory dispensary services. The successful implementation of a clinical pharmacy service to the SCT unit ambulatory clinic allowed for regular contact and review by an experienced clinical pharmacist. This new service was evaluated within the context of a research project. The clinical pharmacist's presence in the ambulatory setting resulted in the identification and rectification of many medium to high risk medication related problems. The clinical pharmacist also contributed towards improved overall adherence. Other institutions are encouraged to implement and evaluate clinical pharmacy services to their ambulatory settings for SCT and other complex chronic patients.
    09/2014; 44(3). DOI:10.1002/jppr.1012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to define the pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following intravenous (IV) and inhalation administration in cystic fibrosis (CF) patients. Six CF subjects were administered nebulized CMS doses of 2 and 4 million international units (IU) and IV CMS infusion of 150 mg of colistin base activity. Plasma, sputum and urine samples were collected for 12 to 24 h post-dose. To assess tolerability, lung function tests, serum creatinine concentrations and adverse effect reports were undertaken. All doses were well tolerated in subjects. The pharmacokinetic parameters for CMS following IV delivery were consistent with previously reported values. Sputum concentrations of formed colistin were maintained below 1.0 mg/L for 12 h post-dose. Nebulization of CMS resulted in relatively high sputum concentrations of CMS and formed colistin when compared to IV administration. The systemic availability of CMS was low following nebulization of 2 and 4 million IU (7.93 ± 4.26% and 5.37 ± 1.36%, respectively) and plasma colistin concentrations were below the limit of quantification. Less than 2 - 3% of the nebulized CMS dose was recovered in urine in 24 h. The therapeutic availability and drug targeting index for CMS and colistin following inhalation when compared to IV delivery were significantly greater than one. Inhalation of CMS is an effective means of targeting CMS and formed colistin into the lungs as high lung exposure and minimal systemic exposure were achieved in CF subjects.
    Antimicrobial Agents and Chemotherapy 02/2014; 58(5). DOI:10.1128/AAC.01705-13 · 4.45 Impact Factor
  • Australian Critical Care 02/2014; 27(1):48–49. DOI:10.1016/j.aucc.2013.10.019 · 1.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients having undergone allogeneic stem cell transplantation (SCT) require complex medication regimens. To ensure the safe and effective management of this patient group, specialised care in a centre with a dedicated and experienced healthcare team is essential. The aim of this study was to evaluate the effectiveness of a specialty clinical pharmacist working in an ambulatory SCT clinic. A prospective cohort study was conducted on patients post SCT and discharged to the ambulatory setting. Patients were reviewed by a clinical pharmacist weekly for six visits. At these visits a medication review was undertaken. Interventions from these reviews were recorded. Interventions were then assigned a risk rating by a multidisciplinary panel. Adherence was also assessed by a Morisky questionnaire and review of dose administration aids. Comparison of data over the six-visit period was undertaken. In total 23 patients were enrolled in the study. All six visits were completed in 17 patients and 161 interventions were recorded at an average of 1.4 interventions per patient visit. The panel rated 40 % of interventions as high risk, 46 % as medium risk and 14 % as low risk. At all visit points high- and medium-risk interventions constituted >80 % of the total. Morisky scores improved by an average of 1.53 (p < 0.0001) between visits 1 and 6. All patients were scored as highly adherent by visit 6. A specialist clinical pharmacist in the SCT outpatient clinic resulted in regular and effective intervention contributing to improved medication management and adherence.
    Supportive Care in Cancer 08/2013; 21(12). DOI:10.1007/s00520-013-1938-9 · 2.50 Impact Factor
  • M J Dooley, S G Poole, D Rischin
    [Show abstract] [Hide abstract]
    ABSTRACT: Oncology clinicians are now routinely provided with an estimated glomerular filtration rate on pathology reports whenever serum creatinine is requested. The utility of using this for the dose determination of renally excreted drugs compared with other existing methods is needed to inform practice. Renal function was determined by [Tc(99m)]DTPA clearance in adult patients presenting for chemotherapy. Renal function was calculated using the 4-variable Modification of Diet in Renal Disease (4v-MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Cockcroft and Gault (CG), Wright and Martin formulae. Doses for renal excreted cytotoxic drugs, including carboplatin, were calculated. The concordance of the renal function estimates according to the CKD classification with measured Tc(99m)DPTA clearance in 455 adults (median age 64.0 years: range 17-87 years) for the 4v-MDRD, CKD-EPI, CG, Martin and Wright formulae was 47.7%, 56.3%, 46.2%, 56.5% and 60.2%, respectively. Concordance for chemotherapy dose for these formulae was 89.0%, 89.5%, 85.1%, 89.9% and 89.9%, respectively. Concordance for carboplatin dose specifically was 66.4%, 71.4%, 64.0%, 73.8% and 73.2%. All bedside formulae provide similar levels of concordance in dosage selection for the renal excreted chemotherapy drugs when compared with the use of a direct measure of renal function.
    Annals of Oncology 08/2013; 24(11). DOI:10.1093/annonc/mdt300 · 6.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Intensive smoking cessation interventions initiated during hospitalisation are effective, but currently not widely available. Strategies are needed to integrate smoking cessation treatment into routine inpatient care. Pharmacist-led interventions for smoking cessation are feasible and efficacious in both ambulatory and community pharmacy settings. However, there is a lack of evidence from large scale studies of the effectiveness of pharmacist guided programs initiated during patient hospitalisation in achieving long-term abstinence. This study aims to evaluate the effectiveness of a pharmacist-led system change intervention initiated during hospitalisation in Australian public hospitals.Methods/design: A multi-centre, randomised controlled trial will be conducted with 12 months follow-up. Smokers, 18 years or older, will be recruited from the wards of three Victorian public hospitals. Participants will be randomly assigned to a usual care or intervention group using a computer generated randomisation list. The intervention group will receive at least three smoking cessation support sessions by a trained pharmacist: the first during the hospital stay, the second on or immediately after discharge and the third within one month post-discharge. All smoking cessation medications will be provided free of charge during the hospital stay and for at least one week after discharge. Participants randomised to usual care will receive the current care routinely provided by the hospital. All measurements at baseline, discharge, one, six and 12 months will be performed by a blinded Research Assistant. The primary outcome measures are carbon monoxide validated 7-day point prevalence abstinence at six and 12 months. DISCUSSION: This is the first large scale study to develop and test a pharmacist-led system change intervention program initiated during patient hospitalisation. If successful, the program could be considered for wider implementation across other hospitals.Trial registration: Australian New Zealand Clinical Trial Registry ACTRN12612000368831.
    Trials 05/2013; 14(1):148. DOI:10.1186/1745-6215-14-148 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antimicrobial stewardship programs are recommended to reduce antimicrobial resistance by reducing inappropriate use of antimicrobials. We implemented an antimicrobial stewardship program and aimed to evaluate its effect on broad-spectrum antimicrobial use. Observational study with historical control using interrupted time series analysis conducted in a tertiary referral hospital. Hospital inpatients prescribed restricted antimicrobials for non-standard indications, where approval had expired or without approval. Baseline period of 30 03s immediately followed by an 18-03 intervention period commencing January 2011. Number and type of interventions made by antimicrobial stewardship team; 03ly rate of use of broad-spectrum antimicrobial agents (in defined daily doses/1000 occupied bed-18s). The antimicrobial stewardship team made 1104 recommendations in 779 patients during the 18-03 intervention period. In 64% of cases, the recommendation was made to cease or de-escalate the antimicrobial therapy, or to change from intravenous to oral therapy. The introduction of the intervention resulted in an immediate 17% (95% CI, 13%-20%) reduction in broad-spectrum antimicrobial use in the intensive care unit and a 10% (95% CI, 4%-16%) reduction in broad-spectrum antimicrobial use outside the intensive care unit. Reductions were particularly seen in cephalosporin and glycopeptide use, although these were partially offset by increases in the use ofβ-lactam-β-lactamase inhibitors. The introduction of an antimicrobial stewardship program, including postprescription review, resulted in an immediate reduction in broad-spectrum antimicrobial use in a tertiary referral centre. However, the effect of this intervention reduced over time.
    The Medical journal of Australia 03/2013; 198(5):262-6. DOI:10.5694/mja12.11683 · 3.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The practice of naturopathy and Western herbal medicine (WHM) was built on traditional evidence but may be undergoing change with the advent of scientific evidence. The aims of this research were to provide a better understanding of practitioners' attitudes towards evidence, information sources, professional regulation and their knowledge about the evidence of commonly used complementary medicines (CMs). Naturopaths and WHM practitioners were invited to participate in an anonymous, self-administered, on-line survey. Participants were recruited using the mailing lists and websites of CM manufacturers and professional associations. Four hundred and seventy nine practitioners participated; 95% currently in practice. The majority (99%) thought well documented traditional evidence was essential or important, 97% patient reports and feedback, 97% personal experience, 94% controlled randomised trials and 89% published case reports. Significantly more recent graduates (less than 5 years) rated randomised trials as essential compared to others. Most (82%) respondents want information sources containing both traditional and scientific evidence. They currently use several resources; 74% CM textbooks, 67% conferences/seminars, 57% CM journals, 48% databases and 40% manufacturers' information. The mean knowledge score was 61.5% with no significant differences between respondents with diploma or degree level education or by graduating year. Eighty-five percent of practitioners strongly agreed or agreed that practitioners should be formally registered to safeguard the public, 8% were unsure and 8% disagreed or strongly disagreed. Naturopaths and WHM practitioners accept the importance of scientific evidence whilst maintaining the importance and use of traditional evidence. The majority are in favour of professional registration.
    Complementary therapies in medicine 02/2013; 21(1):58-64. DOI:10.1016/j.ctim.2012.11.008 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumour lysis syndrome (TLS) is a life-threatening oncological emergency characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia [1,2] due to the rapid lysis of malignant cells, following the initiation of anticancer therapies[3], Traditionally, therapy for TLS involved intensive hydration, urinary alkalinisation and administration of allopurinol [4-6]. Newer guidelines now include rasburicase, with monitoring of electrolytes, white blood cell counts (WCC) and lactate dehydrogenase (LDH) levels. [1,7,8] Rasburicase, a recombinant urate oxidase enzyme, effectively decreases existing serum uric acid (UA) by oxidising it to allantoin which is readily soluble and excretable [3]. © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
    British Journal of Clinical Pharmacology 06/2012; 75(2). DOI:10.1111/j.1365-2125.2012.04355.x · 3.69 Impact Factor
  • Source
    BMC Complementary and Alternative Medicine 06/2012; 12(1). DOI:10.1186/1472-6882-12-S1-P295 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Informing patients about their adverse drug reactions (ADRs) and involving them in their medication management should decrease repeat ADRs. An innovative model for informing patients about their ADRs has been in place at an Australian health network. The health network's ADR Review Committee reviews the ADR reports, assigns causality and makes recommendations. Patients are sent a letter about their ADR along with an alert card.AimTo evaluate the existing ADR model.Method Over a 6-month period, patients who had an ADR report reviewed by the ADR Review Committee were contacted by telephone within 4 weeks of the review and asked questions about the ADR information sent to them. Patients' discharge summaries were concurrently reviewed for ADR information. Feedback about the model was also sought from the hospital's consumer groups.ResultsOf the 89 ADR reports reviewed, 76 patients were eligible, and 55 (72%) patients consented to participate in the survey. 50 (91%) patients recalled the name of the causative drug, 53 (96%) recalled the reaction, 48 (87%) recalled the ADR Review Committee's recommendation, 28 (50%) had an alert card in their wallet, and 29 (52%) had shown or were intending to show the letter to their doctor, but only 3 to their pharmacist. 95% of respondents would recommend this model to other hospitals. 35 (63%) patients wanted the letter sent directly to their doctor. Of the 54 discharge summaries reviewed, the ADR was documented in 43 (80%), details of the reaction in 43 (80%) and specific management advice in 10 (19%). Feedback from the hospital's consumer groups (n = 15) was positive and informed improvements to the model.Conclusion The ADR model was well received by patients, who retained the information sent. Patient feedback was used to improve the format and content of the ADR information sent. This model could be adapted by other acute and ambulatory settings to facilitate communication between health professionals and patients to avoid repeat ADRs.
    Journal of Pharmacy Practice and Research 06/2012; 42(2):95. DOI:10.1002/j.2055-2335.2012.tb00142.x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the bias and precision of different methods of estimating body mass and height in hospitalized adult patients. Patients were enrolled at the Alfred and Caulfield hospitals, Melbourne, Australia following verbal consent. Estimates were made using the Lorenz formula (that utilizes height, waist and hip circumference), the Crandell formula (that utilizes height and arm circumference) and visual estimation of weight based on the average results obtained by two pharmacy interns. Statistical error was calculated as the ratio of estimated to actual weight; bias was assessed as the mean error and precision as the proportion of estimates within 10 and 20% of measured weight and standard deviation of the error. In a 5-week period July to August 2010, 198 patients were enrolled. The median age was 64 years (range 19-91) and 52% were female. Thirty-four (17%) patients were obese (BMI >30 kg/m(2)) and 8 (4%) were underweight (BMI <18 kg/m(2)). With the Lorenz formula an estimate within 10% was obtained for 56% of patients; with the Crandell formula prediction was poor. Documentation of body weight in notes and patient self-reporting were both accurate. Seventy-two patients (43%) were prescribed one or more drugs for which dosing potentially should be adjusted for body weight. In adult hospitalized patients, the estimation of body weight by anthropomorphic measures is not accurate. This supports the need for equipment to be made widely available to accurately weigh patients directly in hospital, including in unconscious and immobile patients.
    QJM: monthly journal of the Association of Physicians 04/2012; 105(8):769-74. DOI:10.1093/qjmed/hcs060 · 2.46 Impact Factor
  • M. Dooley, K. Tan, S. G. Poole
    European Journal of Hospital Pharmacy 03/2012; 19(2):148-149. DOI:10.1136/ejhpharm-2012-000074.169 · 0.47 Impact Factor
  • European Journal of Hospital Pharmacy 03/2012; 19(2):215-216. DOI:10.1136/ejhpharm-2012-000074.342 · 0.47 Impact Factor
  • M. Dooley, S. G. Poole
    European Journal of Hospital Pharmacy 03/2012; 19(2):193-194. DOI:10.1136/ejhpharm-2012-000074.286 · 0.47 Impact Factor
  • M J Dooley, M Wiseman, G Gu
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of error-prone abbreviations in prescribing is a potential cause of misinterpretation that may lead to medication error. This study determined frequency and type of error-prone abbreviations in inpatient medication prescribing across three Australian hospitals. Three hundred and sixty-nine (76.9%) patients had one or more error-prone abbreviations used in prescribing, with 8.4% of orders containing at least one error-prone abbreviation and 29.6% of these considered to be high risk for causing significant harm.
    Internal Medicine Journal 03/2012; 42(3):e19-22. DOI:10.1111/j.1445-5994.2011.02697.x · 1.70 Impact Factor
  • The Medical journal of Australia 01/2012; 196(1):34-5. DOI:10.5694/mja11.10809 · 3.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Optimization of the timing of appropriate antibiotics is crucial to improve the management of patients in severe sepsis and septic shock. Vancomycin is commonly used empirically in cases of nosocomial infections in critically ill patients. Therefore, early optimization of vancomycin pharmacokinetics is likely to improve outcomes. To evaluate a pharmacokinetic program to predict serum vancomycin concentrations in accordance with administered dose, weight, height, and creatinine clearance in a critically ill population. We conducted a prospective observational single-center study in a 45-bed intensive care unit (ICU). All patients hospitalized in the ICU requiring intravenous treatment with vancomycin for a suspected infection were enrolled. The modalities of vancomycin therapy and the monitoring of serum concentrations were left to the discretion of the treating clinician. We compared the measured serum vancomycin concentrations with those predicted by the MM-USCPACK program and analyzed the factors influencing the prediction. Fifty-four intravenous vancomycin courses were administered in 48 critically ill patients over the 3-month study. The precision was considered acceptable, based on a relative precision equal to 8.9% (interquartile range 3.5-18.9%) and the relative bias for all predictions was equal to -1.3%. Overall, 77.3% of predictions were within 20% of observed concentrations; factors correlating with a poorer prediction were a change in renal function, obesity, and the magnitude of organ dysfunction on initiation of vancomycin (expressed by a Systemic Organ Failure Assessment score >11). The MM-USCPACK program is a useful and reliable tool for prediction of serum vancomycin concentrations in patients hospitalized in ICU and likely reflects the close monitoring of renal function in this setting. For some patients (more severely ill, obese, or significant change in renal function during vancomycin therapy), predictions were less precise.
    Annals of Pharmacotherapy 09/2011; 45(10):1193-8. DOI:10.1345/aph.1Q195 · 2.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin is a high-risk medicine which may cause significant patient harm or death when given incorrectly. A 10-fold error in administered insulin dose commonly occurs when the abbreviation 'u' is used for 'units' and subsequently misinterpreted as a 'zero.' A multidisciplinary working party was convened and mapped insulin prescribing, dispensing and administration. All inpatient orders above 25 units for short-acting insulin and 50 units for other insulin require validation by an additional source. Educational strategies to support adherence to the guideline and product-labelling alerts were developed. Implementation occurred in August 2008 across the three hospital sites. In 90 weeks after implementation, there were 150 patients identified in which 200 high doses of insulin were prescribed (>25 units for short-acting insulin and 50 units for other insulin). There were eight instances where high doses of insulin were prescribed in error but were detected and rectified through the new validation process. There were 12 dosing errors that occurred, including two 10-fold dosing errors. In contrast, seven major errors resulting in excessive insulin administration were identified over a 2-year period prior to the introduction of the insulin high-dose validation system. A structured validation process was successful in reducing incorrect prescription and administration of high-dose insulin and has reduced the risk of associated fatalities or significant patient harm. Consideration should be given to adopting this process in any setting where insulin is prescribed and administered.
    BMJ quality & safety 07/2011; 20(7):637-44. DOI:10.1136/bmjqs.2010.049668 · 3.28 Impact Factor

Publication Stats

516 Citations
197.07 Total Impact Points


  • 2014
    • Melbourne Health
      Melbourne, Victoria, Australia
  • 2005–2014
    • University of Vic
      Vic, Catalonia, Spain
  • 2004–2014
    • Monash University (Australia)
      • Faculty of Pharmacy and Pharmaceutical Sciences
      Melbourne, Victoria, Australia
  • 2008–2010
    • Alfred Hospital
      • Department of Pharmacy
      Melbourne, Victoria, Australia
    • Eastern Health Australia
      Box Hill, Victoria, Australia
  • 2007
    • Institut Paoli Calmettes
      Marsiglia, Provence-Alpes-Côte d'Azur, France
  • 2002–2006
    • Victorian College for the Deaf
      Melbourne, Victoria, Australia
  • 2000–2005
    • Peter MacCallum Cancer Centre
      • Pharmacy Division
      Melbourne, Victoria, Australia